Get informed when a big investor buys or sells
+ FollowUndervalued by 128.5% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $55.04 Million |
|---|---|
| Enterprise Value | $55.02 Million |
| Earnings per Share | $-11.93 |
| Beta | 1.64 |
| Outstanding Shares | 14,296,323 |
| P/E Ratio | -0.21 |
|---|---|
| PEG | -0.01 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -0.87 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.